

Dave & Buster's Entertainment, Inc.
 Form 3
 October 09, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>OHCP MGP III, LTD.</p> <p>(Last) (First) (Middle)</p> <p>201 MAIN STREET, SUITE 1018</p> <p>(Street)</p> <p>FORT WORTH, TX 76102</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>10/09/2014</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Dave & Buster's Entertainment, Inc. [PLAY]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p>
--	---	--	---	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.01 par value	30,656,879	I	See footnotes (1) (3) (4)
Common Stock, \$0.01 par value	1,006,843	I	See footnotes (2) (3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	------------------------------------	---------------------------------	--

Edgar Filing: Dave & Buster's Entertainment, Inc. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)
------------------	-----------------	-------	----------------------------	---------------------	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
OHCP MGP III, LTD. 201 MAIN STREET SUITE 1018 FORT WORTH, TX 76102	^	^ X	^	^
Oak Hill Capital Partners III, L.P. 201 MAIN STREET SUITE 1018 FORT WORTH, TX 76102	^	^ X	^	^
Oak Hill Capital Management Partners III, L.P. 201 MAIN STREET SUITE 1018 FORT WORTH, TX 76102	^	^ X	^	^
OHCP GenPar III, L.P. 201 MAIN STREET SUITE 1018 FORT WORTH, TX 76102	^	^ X	^	^
OHCP MGP PARTNERS III, L.P. 201 MAIN STREET SUITE 1018 FORT WORTH, TX 76102	^	^ X	^	^

Signatures

/s/ Tyler J. Wolfram, Vice President 10/09/2014

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These securities are held by Oak Hill Capital Partners III, L.P.

(2) These securities are held by Oak Hill Capital Management Partners III, L.P.

The general partner of Oak Hill Capital Partners III, L.P. and Oak Hill Capital Management Partners III, L.P. is OHCP GenPar III, L.P.

(3) The general partner of OHCP GenPar III, L.P. is OHCP MGP Partners III, L.P. The general partner of OHCP MGP Partners III, L.P. is OHCP MGP III, Ltd.

Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting

(4) Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

Â

Remarks:

Exhibit 99.1 - Additional Signatures

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. width="76%">

CURRENT LIABILITIES:

Current maturities of long-term debt

\$12,193 \$11,974

Trade payables and other current liabilities

238,302 241,330

TOTAL CURRENT LIABILITIES

250,495 253,304

Long-term debt, net of current maturities

5,665 5,888

Deferred income taxes and other long-term liabilities

4,667 4,591

TOTAL LIABILITIES

260,827 263,783

Taro shareholders' equity

1,080,759 1,015,507

Non-controlling interest

5,186 5,086

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

\$1,346,772 \$1,284,376

Taro Pharmaceutical Industries Ltd.

Page 5 of 5

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

(U.S. dollars in thousands)

	Three Months Ended June 30,	
	2014	2013
Operating Activities		
Net income	\$46,198	\$58,946
Adjustments required to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	3,964	4,234
Gain on sale of marketable securities and long-lived assets	(39)	(112)
Increase in long-term debt due to currency fluctuations	206	310
Decrease in trade receivables	35,636	2,881
Change in derivative instruments, net	(3,989)	2,969
Increase in other receivables, prepaid expenses and other assets	(42,651)	(14,415)
Increase in inventories	(8,656)	(4,058)
Foreign exchange effect on intercompany balances	5,209	(3,856)
(Decrease) increase in trade and other payables and accruals	(144)	17,512
Net cash provided by operating activities	35,734	64,411
Investing Activities:		
Purchase of property plant & equipment	(6,058)	(3,898)
Proceeds from sale of property plant & equipment and intangible assets	78	-
Investment in long-term deposits and other assets	(14,708)	-
Proceeds from (investment in) short-term and restricted bank deposits	90,078	(20,694)
Proceeds from sale of marketable securities	-	365
Net cash provided by (used in) investing activities	69,390	(24,227)
Financing Activities:		
Excess tax benefits from share-based payment arrangements	-	21
Proceeds from the issuance of shares, net	13	298
Repayments of long-term debt	(209)	(197)
Net cash (used in) provided by financing activities	(196)	122
Effect of exchange rate changes	2,978	(4,032)
Net increase in cash	107,906	36,274
Cash at beginning of period	209,967	237,284
Cash at end of period	\$317,873	\$273,558

#####

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 7, 2014

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: /s/ Subramanian Kalyanasundaram

Name: Subramanian Kalyanasundaram

Title: Chief Executive Officer and
Director